65,437 trials
Non Small Cell Lung Cancer
Primary: Event-Free Survival (EFS) — 20.80; 31.57 Months — p=0.0052
Sepsis · Septic Shock
Primary: Mortality Rates — 12; 7 Participants — p=0.344
Triple Negative Breast Cancer · TNBC - Triple-Negative Breast Cancer
Primary: Overall Response Rate (ORR) — 22.2; 10.0; 10.5; 53.8 percentage of participants — p=0.2252
Epilepsy · Schizophrenia · Schizoaffective Disorder
Primary: Change in Montgomery Asberg Depression Rating Scale (MADRS) — 16.75; 22.94; 11.21; 21.81 score on a scale — p=0.036
Relapsing Remitting Multiple Sclerosis
Primary: Proportion of Subjects That Experience a Relapse — 0.32; 0.34 proportion of participants — p=0.60
HIV-1-infection
Primary: Number of Participants With Adherence to PrEP at 6 Months — 95; 106; 94 Participants
Stroke · Hemiplegia
Primary: Correlation Between Scheduled and Performed Trainings — 0.56 correlation coefficient
Depression · Suicidal Ideation
Primary: Number of Participants Referred to Treatment — 0; 1; 0; 0 Participants
Sensorineural Hearing Loss
Primary: CNC (Consonant-nucleus-consonant) Words — 64.8 percentage of correct words.
Leukemia
Primary: Number of Patients With Complete Remission at One Year — 12; 13 Participants
Advanced Malignancies
Primary: Phase 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 4; 4; 5; 5 Participants
Pain, Acute
Primary: Level of Pain as Observed by Two Independent Observers Following Propofol Injection, With or Without a Vibration Analgesia Adjunct — 3.1; 1.4 units on a scale
Diabetes · Deafness
Primary: Diabetes Health Literacy Score — 1.30; 1.38 score on a scale — p=0.95
Atopic Dermatitis
Primary: Investigator's Global Assessment (IGA) — 12; 18; 87; 77 Participants
Metastatic Non-small Cell Lung Cancer · NSCLC
Primary: Number of Subjects With Treatment-Emergent Adverse Events (TEAEs) — 23; 33; 13; 19 Participants